Serum Institute of India applies for emergency approval of covid vaccine candidate ?Covishield?

Published by
Archive Manager

Serum Institute of India (SII) has applied for emergency approval of made-in-India covid vaccine candidate, Covishield. SII CEO Adar Poonawalla has confirmed it and said it will save countless lives.
Adar Poonawalla also thanked the Government of India and Prime minister Narendra Modi for their invaluable support. SII, the world’s largest vaccine producer by volume, had sought emergency use authorization in the country for AstraZeneca Plc’s COVID-19 vaccine candidate.
The company applied to the Drugs Controller General of India, citing unmet medical needs due to the pandemic and in the interest of the public at large. The move comes close on the heels of Pfizer Inc applying for a similar authorisation of its coronavirus vaccine in India.
Share
Leave a Comment